Netherlands’ Norgine Sets Up OTC Business And Targets Acquisitions
Executive Summary
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.
You may also be interested in...
People On The Move: Appointments At GSK, Reckitt And Norgine
A round-up of the latest health and wellness appointments: GSK makes addition to senior management teams in Europe; Reckitt appoints general counsel; and Norgine announces CEO change.
Norgine Drives Role As Specialty Partner For Europe
The mid-sized pharmaceutical company Norgine aims to grow its specialty business in Europe through targeted business development activities, while at the same time separating out its consumer healthcare activities into a new subsidiary.
With Investor Support Thin On The Ground, Unilever Won't Up Bid For GSK Consumer Healthcare
Unilever's decision not to increase its £50bn bid for GSK Consumer Healthcare has been widely welcomed by analysts. But they warn that the aborted move for GSK has damaged investor confidence in Unilever’s management.